MedPath

The randomized trial of mixed amino acid medication to prevent post-ERCP pancreatitis

Not Applicable
Conditions
post-ERCP pancreatitis
Registration Number
JPRN-UMIN000011516
Lead Sponsor
Yokohama City University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
400
Inclusion Criteria

Not provided

Exclusion Criteria

1) who we could not achieve informed concent, 2) who we evaluated inappropriate for thos trial, 3) who had poor performance status, 4) were under 20 years old, 5) to who ERCP was not completed, 6) who had acute or active pancreatitis, and 7) who had low risk factors of PEP: a) choronic pancreatitis, b) periodical stent exchange, c) ERC to pancreas divisum, and d) the past history of papilla disposal (ex. EST, EPBD and EP).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1) new abdominal pain. 2) eleuation in pancreatic enzymes to at least three times the upper limit of the normal range 24 hours after ERCP. 3) extension of hospitalization or medical treatment at least two days.
Secondary Outcome Measures
NameTimeMethod
adverse event
© Copyright 2025. All Rights Reserved by MedPath